EA201170131A1 - Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1) - Google Patents

Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1)

Info

Publication number
EA201170131A1
EA201170131A1 EA201170131A EA201170131A EA201170131A1 EA 201170131 A1 EA201170131 A1 EA 201170131A1 EA 201170131 A EA201170131 A EA 201170131A EA 201170131 A EA201170131 A EA 201170131A EA 201170131 A1 EA201170131 A1 EA 201170131A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mtgpat1
phosphataciltransferase
phk
mitochondrial
glycerin
Prior art date
Application number
EA201170131A
Other languages
English (en)
Russian (ru)
Inventor
Мари Линдхолм
Эллен Мари Строруп
Original Assignee
Сантарис Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантарис Фарма А/С filed Critical Сантарис Фарма А/С
Publication of EA201170131A1 publication Critical patent/EA201170131A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01015—Glycerol-3-phosphate O-acyltransferase (2.3.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201170131A 2008-07-03 2009-06-24 Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1) EA201170131A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7794208P 2008-07-03 2008-07-03
EP08104623 2008-07-03
PCT/EP2009/057907 WO2010000656A1 (en) 2008-07-03 2009-06-24 Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1)

Publications (1)

Publication Number Publication Date
EA201170131A1 true EA201170131A1 (ru) 2011-08-30

Family

ID=41066150

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170131A EA201170131A1 (ru) 2008-07-03 2009-06-24 Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1)

Country Status (11)

Country Link
US (1) US20120004276A1 (enExample)
EP (1) EP2310504A1 (enExample)
JP (1) JP2011526482A (enExample)
KR (1) KR20110031368A (enExample)
CN (1) CN102076854A (enExample)
AU (1) AU2009265836A1 (enExample)
BR (1) BRPI0915837A2 (enExample)
CA (1) CA2729897A1 (enExample)
EA (1) EA201170131A1 (enExample)
MX (1) MX2010013552A (enExample)
WO (1) WO2010000656A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101914309B1 (ko) * 2010-06-23 2018-11-02 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
US20140050728A1 (en) * 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
CN104583398A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节基因表达的组合物和方法
SG10201804331TA (en) 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
US20150368642A1 (en) * 2013-01-30 2015-12-24 Hoffmann-La Roche Inc. Lna oligonucleotide carbohydrate conjugates
CN105039513B (zh) * 2015-05-29 2018-12-28 广州市第一人民医院 用于非酒精性脂肪肝相关目的基因多态性检测方法及其引物，以及试剂盒
CN104997768B (zh) * 2015-07-23 2017-11-17 上海市第六人民医院 鱼藤酮在制备降血糖药物中的应用
US20230203496A1 (en) * 2020-06-09 2023-06-29 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
GB202015056D0 (en) * 2020-09-23 2020-11-04 Cambridge Entpr Ltd Biomarkers
KR20230151996A (ko) * 2021-02-27 2023-11-02 리제너론 파마슈티칼스 인코포레이티드 미토콘드리아 글리세롤-3-인산염 아실전이효소 (gpam)억제제를 이용한 간 질환의 치료
CN118525091A (zh) * 2021-10-22 2024-08-20 安进公司 用于抑制gpam表达的rnai构建体及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048316A2 (en) * 2001-11-30 2003-06-12 Bristol-Myers Squibb Company Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes

Also Published As

Publication number Publication date
MX2010013552A (es) 2011-03-24
CN102076854A (zh) 2011-05-25
US20120004276A1 (en) 2012-01-05
AU2009265836A1 (en) 2010-01-07
EP2310504A1 (en) 2011-04-20
KR20110031368A (ko) 2011-03-25
WO2010000656A1 (en) 2010-01-07
BRPI0915837A2 (pt) 2015-11-03
JP2011526482A (ja) 2011-10-13
CA2729897A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
MX2010013552A (es) Compuestos antagonistas de arn para la inhibicion de expresion de glicerol-3-fosfato aciltransferasa mitocondrial 1 (mtgpat1).
EA201190325A1 (ru) Специфичные к меланокортиновым рецепторам пептиды
MX2011005965A (es) Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
EA201490913A1 (ru) Лекарственные формы для лечения сахарного диабета
MY154484A (en) Treatment of virally induces lesions
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
CO6321252A2 (es) Derivados de quinoxalindiona
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2007003176A1 (es) Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
WO2015095354A3 (en) Compositions and methods for treating fatty tissue buildup
PH12014501442A1 (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
MX360317B (es) Derivados de exendina-4 funcionalizada.
EA201300759A1 (ru) Новые производные nip тиазола в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы-1
WO2011041385A3 (en) Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
PH12014501441B1 (en) Derivatives of aza adamantane and uses thereof
EA201301308A1 (ru) Комбинация для лечения сахарного диабета